Nigericin
WikiDoc Resources for Nigericin |
Articles |
---|
Most recent articles on Nigericin |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Nigericin at Clinical Trials.gov Clinical Trials on Nigericin at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Nigericin
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Nigericin Discussion groups on Nigericin Directions to Hospitals Treating Nigericin Risk calculators and risk factors for Nigericin
|
Healthcare Provider Resources |
Causes & Risk Factors for Nigericin |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Nigericin is an antibiotic derived from Streptomyces hygroscopicus. Commercially it is obtained as a byproduct, or contaminant, at the fermentation of Geldanamycin. It is also called Polyetherin A, Azalomycin M, Helixin C, Antibiotic K178, Antibiotic X-464.
Nigericin acts as an H+, K+, Pb++ ionophore. It most commonly is an antiporter of H+ and K+.
In the past Nigericin was used as an antibiotic active against gram positive bacteria. It inhibits the Golgi functions. Nigericin exhibits anti-HIV activity.
Properties
- CAS number: 28643-80-3
- Merck index: 12, 6633
- Molecular weight: 747
- Formula C40H67O11Na
The properties are copied from a manufacturer's Nigericin product page]